Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 14.5% on Monday . The stock traded as low as C$0.27 and last traded at C$0.27. 438,482 shares were traded during trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Trading Up 3.8 %
The stock has a fifty day moving average of C$0.11 and a 200-day moving average of C$0.08. The firm has a market capitalization of C$23.96 million, a price-to-earnings ratio of -13.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
- What Is WallStreetBets and What Stocks Are They Targeting?
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Retail Trends Spark Analyst Upgrades for DICK’s Sporting Goods
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
